CAR T-cells have been extensively utilized in several hematologic malignancies in recent years, and owing to their efficacy in improving patient outcomes, the FDA approved them for lymphoma and leukemia [139]. In B cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, and c...
(PD-L1), has enabled T cell-mediated tumor regression for a range of malignancies including melanoma [9, 10], ovarian [11], lung [12], bladder [13], renal-cell carcinoma [14], Hodgkin’s lymphoma [15], as well as colorectal, gastrointestinal and endometrial cancers having DNA mismatch ...
In CAR T-cell therapy, CD19 is a prevalent target for blood cancer treatment. Screening CD19+expression in B cell precursor acute lymphoblastic leukemia (BCP-ALL) revealed the contrasting functions of Zinc Finger Protein 143 and Nudix Hydrolase 21 (NUDT21). The absence of NUDT21 in BCP-ALL ...
lymphoblastic leukemia (B-ALL), B cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and multiple myeloma (MM), although more improvements are needed for treating chronic lymphocytic leukemia (CLL) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18...
The chromosomal translocation t(7;9) in human T-cell acute lymphoblastic leukaemia (T-ALL) results in deregulated expression of a truncated, activated form of Notch 1 (TAN1) under the control of the T-cell receptor-β (TCRB) locus. Although TAN1 efficiently induces T-ALL in mouse models...
J.E. and A.C. performed experiments. X.W. and I.R. generated and provided clinical experimental materials. R.A., T.L., R.C. and B.V. generated TiPS lines, developed iCD34 methodology. M.T. and I.R. contributed to experimental design and data analysis. M.S. designed the study,...
Chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of CD19- and B-cell maturation antigen-positive haematological malignancies. However, the effect of a CAR construct on the function of T-cells stimulated via their endogenous T-cel
Codes for acute lymphoblastic leukemia (ALL), DLBCL (diffuse large B-cell lymphoma), multiple myeloma (MM,) Follicular lymphoma (FH), Mantle Cell Lymphoma (MCL) were used to identify the indication. Patients without these indications were categorized as "Others". Appropriate weights were applied ...
Before the FDA approval of two chimeric antigen receptor T-cell therapies, children and young adults with B-cell acute lymphoblastic leukemia and adults with relapsed or refractory diffuse large B-cell lymphoma were considered incurable.Chimeric antigen
Due to its inherent high specificity, CAR-T cell therapy has been successful in the treatment of hemato- logic malignancies like acute lymphoblastic leukemia but has shown limited efficacy in solid tumors. Unlike CAR- T's single receptor, TCR-T immunotherapy employs the natural T-cell receptor ...